Germany’s Vaccine Demand Set to Continue Outstripping Supply
(Bloomberg) -- Demand for Covid-19 vaccines in Germany will continue to outstrip supply for several more weeks as the country nears the milestone of administering a first shot to half the population, according to Health Minister Jens Spahn.
“We are still moving forward at high speed, but I know that demand is still exceeding supply and it will remain the case for several weeks more,” Spahn said Friday in an interview with Inforadio. “But we are talking about weeks rather than months and that means we have good prospects for the rest of the summer.”
After a sluggish start, Germany's vaccination drive has accelerated in recent months, and company doctors are due to join the campaign starting next week. More than 50 million doses had been administered as of Thursday, with roughly a fifth of the population fully inoculated, according to health ministry data.
As the campaign gathers speed and Germany's infection rate drops, restrictions are being lifted across the country. Incidence per 100,000 people over the past seven fell below 30 on Friday after climbing to almost 170 on April 26, figures from the RKI public-health institute show.
Spahn said that while Germany's campaign is lagging Britain's by three to four weeks, everyone at age 12 years and older should be able to get a first shot by the end of August.
The U.K. has fully vaccinated almost 40% of its population, and the U.S. just over 40%, according to the Bloomberg Vaccine Tracker.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.